Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001011321 | SCV001171627 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-02-15 | criteria provided, single submitter | clinical testing | The p.T466A variant (also known as c.1396A>G), located in coding exon 14 of the POLE gene, results from an A to G substitution at nucleotide position 1396. The threonine at codon 466 is replaced by alanine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV001868290 | SCV002108988 | uncertain significance | Colorectal cancer, susceptibility to, 12 | 2022-10-07 | criteria provided, single submitter | clinical testing | This sequence change replaces threonine, which is neutral and polar, with alanine, which is neutral and non-polar, at codon 466 of the POLE protein (p.Thr466Ala). This variant is present in population databases (rs761765763, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with POLE-related conditions. ClinVar contains an entry for this variant (Variation ID: 560020). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt POLE protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Baylor Genetics | RCV001868290 | SCV004203548 | uncertain significance | Colorectal cancer, susceptibility to, 12 | 2023-08-01 | criteria provided, single submitter | clinical testing | |
3DMed Clinical Laboratory Inc | RCV000677898 | SCV000804059 | uncertain significance | Colon cancer | 2017-06-15 | no assertion criteria provided | clinical testing |